- Home
- MRSN vs ACV Comparison
MRSN vs ACV Comparison
Compare MRSN & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ACV
- Stock Information
- Founded
- MRSN 2001
- ACV 2015
- Country
- MRSN United States
- ACV United States
- Employees
- MRSN N/A
- ACV N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ACV Finance/Investors Services
- Sector
- MRSN Health Care
- ACV Finance
- Exchange
- MRSN Nasdaq
- ACV Nasdaq
- Market Cap
- MRSN 230.0M
- ACV 216.7M
- IPO Year
- MRSN 2017
- ACV N/A
- Fundamental
- Price
- MRSN $2.21
- ACV $21.40
- Analyst Decision
- MRSN Buy
- ACV
- Analyst Count
- MRSN 6
- ACV 0
- Target Price
- MRSN $6.00
- ACV N/A
- AVG Volume (30 Days)
- MRSN 1.1M
- ACV 38.8K
- Earning Date
- MRSN 11-13-2024
- ACV 01-01-0001
- Dividend Yield
- MRSN N/A
- ACV 9.20%
- EPS Growth
- MRSN N/A
- ACV N/A
- EPS
- MRSN N/A
- ACV N/A
- Revenue
- MRSN $34,837,000.00
- ACV N/A
- Revenue This Year
- MRSN N/A
- ACV N/A
- Revenue Next Year
- MRSN $7.15
- ACV N/A
- P/E Ratio
- MRSN N/A
- ACV N/A
- Revenue Growth
- MRSN N/A
- ACV N/A
- 52 Week Low
- MRSN $1.22
- ACV $16.82
- 52 Week High
- MRSN $6.28
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- MRSN 51.26
- ACV 49.21
- Support Level
- MRSN $2.12
- ACV $22.00
- Resistance Level
- MRSN $2.83
- ACV $22.34
- Average True Range (ATR)
- MRSN 0.24
- ACV 0.30
- MACD
- MRSN 0.03
- ACV 0.06
- Stochastic Oscillator
- MRSN 39.81
- ACV 44.79
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It seeks to achieve its investment objective by investing in a combination of convertible securities, debt and other income-producing instruments and common stocks and other equity securities.